Form 4: Celldex Therapeutics Executive Receives Stock Options

Celldex Therapeutics reports the grant of incentive stock options to SVP & General Counsel Freddy A. Jimenez.

Summary

• Freddy A. Jimenez, SVP & General Counsel at Celldex Therapeutics, was granted 93,000 incentive stock options.
• The options have an exercise price of $34.09 and were granted on June 25, 2026.
• These options are part of the company's 2021 Omnibus Equity Incentive Plan.
• Vesting begins on June 25, 2027, with 25% vesting on that date, and the remaining 75% vesting quarterly over the subsequent 12 quarters.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard executive compensation event (stock option grant) rather than a significant financial or strategic development for the company.

Positives

• Grant of stock options to a key executive can indicate management confidence in future company performance.
• The incentive stock options are designed to align executive interests with shareholder value creation.

Risks

• The value of the stock options is contingent on the future performance of Celldex Therapeutics' stock price.
• If the stock price does not exceed the exercise price of $34.09, the options may not be exercised profitably.

Future Outlook

The future outlook for the stock options is dependent on the company's stock performance and the successful vesting of the options.

Industry Context

StockSavvy.ai notes that the grant of stock options to senior executives is a common practice in the biotechnology and pharmaceutical sectors to attract, retain, and incentivize talent, especially in companies focused on drug development where long-term performance is crucial.

Stakeholder Impact

• Shareholders: The grant of options dilutes existing ownership slightly, but is intended to align executive incentives with long-term shareholder value.
• Employees: May signal a positive outlook for the company, potentially boosting morale.
• Management: Provides a financial incentive for Freddy A. Jimenez to perform well and increase shareholder value.

Next Steps

• Vesting of stock options over the next 12 quarters following June 25, 2027.
• Potential exercise of options by Freddy A. Jimenez if the stock price is favorable.

Key Dates

Keywords

Celldex Therapeutics, CLDX, Form 4, Stock Options, Incentive Stock Option, Executive Compensation, Equity Incentive Plan, Freddy A. Jimenez, SEC Filing